Illinois halts poultry exhibitions, sales events due to bird flu concerns
The 30-day suspension, issued on Tuesday, Feb. 11, prohibits the exhibition or sale of poultry at swap meets, exhibitions, flea markets, and auction markets. According to IDOA, the action aims to reduce and prevent the spread of the disease, which has been detected in Illinois.
Dr. Mark Ernst, IDOA state veterinarian, said prevention is the state's most effective tool to mitigate the spread of the H5N1 bird flu.
Dozens of ducks found dead along shoreline of Northwest Indiana beach
'By being proactive in biosecurity and limiting poultry movement and exposure, we are protecting the public as well as the poultry industry,' Ernst said.
Avian flu is caused by an influenza type A virus, which can infect poultry such as chickens, turkeys, pheasants, quail, domestic ducks, geese, and guinea fowl and wild birds (especially waterfowl.
IDOA reminded poultry flock owners, managers, and veterinarians to immediately report any unusual findings in domestic poultry, such as an increase in mortality, decrease in water consumption, decrease in egg production, or respiratory signs, including coughing and sneezing.
Officials also warned locals who encountered a dead bird to call Animal Control or the Health Department.
No human H5N1 bird flu cases have been confirmed in Illinois, IDPH director Dr. Sameer Vohra said.
Second type of bird flu detected in US dairy cows
'IDPH continues to monitor human exposures very closely,' Vohra said. 'We are committed to using every tool at our disposal to enhance our preparation, communication, and education to help combat H5N1.'
Sign up for our Medical Watch newsletter. This daily update includes important information from WGN's Dina Bair and the Med Watch team, including, the latest updates from health organizations, in-depth reporting on advancements in medical technology and treatments, as well as personal features related to people in the medical field. Sign up here.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time Business News
33 minutes ago
- Time Business News
Why Spider Control Is Now a Top Priority for Naperville Homeowners in 2025
In 2025, spider control Naperville has quickly risen to the top of many homeowners' to-do lists—and for good reason. With changing climate patterns, increased urban sprawl, and seasonal surges in pest activity, spider infestations are no longer a minor inconvenience—they're becoming a recurring concern. Naperville residents are now taking proactive steps to secure their homes, particularly during late summer and early fall when spider activity peaks. If you've noticed more webs, sightings, or even bites, you're not alone—and you're right to take action. Experts from pest control associations like the National Pest Management Association (NPMA) and local providers cite several contributing factors behind the surge in spider presence in suburban areas like Naperville. Warmer winters and wetter springs have created ideal conditions for insects—spiders' primary food source—to thrive. This abundance of prey is drawing more spiders into residential spaces, particularly basements, garages, and crawlspaces. Increased home renovations and urban landscaping also create more nesting opportunities. As more homes opt for energy efficiency upgrades and tight-sealed insulation, spiders are forced to enter through vents, attic gaps, and utility lines. The result? Naperville homes are becoming spider-friendly environments—unless proactive measures are taken. While many spiders are harmless and even beneficial for controlling insects, certain species pose health and safety risks. The brown recluse and black widow, both found in Illinois, can deliver venomous bites that require medical attention. Even non-venomous spiders like the common house spider or cellar spider can cause alarm when they invade in large numbers, particularly in homes with young children, elderly residents, or anyone with arachnophobia. According to the Illinois Department of Public Health (IDPH), while serious bites are rare, infestations can lead to skin irritation, allergic reactions, and mental stress. Spider droppings, egg sacs, and deceased insects also contribute to poor indoor air quality, especially in poorly ventilated areas like attics and basements. For residents searching for safe, effective, and affordable spider control in Naperville, Yosemite Pest & Rodent Solutions stands out as a trusted local provider. Backed by over 30 years of experience in pest management, their team is IDPH-certified, fully insured, and trained in Integrated Pest Management (IPM) techniques. This means they don't just treat the symptoms of infestations—they focus on eliminating the root cause and preventing re-entry. Yosemite offers free home inspections, no-contract pest control plans, and same-day emergency service—perfect for families dealing with a sudden infestation or those preparing for seasonal prevention. Their services are eco-friendly, pet-safe, and tailored specifically for Naperville's climate and housing structures. Effective spider control isn't just about spraying chemicals—it requires a comprehensive strategy. Yosemite Pest begins with a detailed inspection to identify entry points, spider species, and infestation levels. Treatments typically include targeted pesticide applications in high-risk zones (like baseboards, crawlspaces, and garages), removal of webs and egg sacs, and sealing of cracks and entry gaps. In addition to chemical treatments, prevention is key. Homeowners receive education on minimizing moisture, reducing clutter, and managing exterior lighting (which attracts insects, and therefore spiders). Seasonal maintenance visits are often recommended, especially during peak spider months between August and October. The best time to schedule spider control is before the infestation reaches critical levels. Many Naperville homeowners wait until fall, when spiders are most visible—but early summer treatments can significantly reduce populations before they enter the home. Likewise, homes with recurring infestations or older foundations should consider bi-annual treatments for year-round protection. Additionally, if you're noticing webs in corners, increased insect activity, or spider sightings in daylight hours, these are strong signs that the infestation has already taken hold. In such cases, immediate intervention is recommended to avoid the development of hidden nests and large egg sacs. Spiders favor dark, undisturbed spaces, and Naperville homes offer plenty of them—especially in: Basements and crawlspaces Attics and utility closets Behind furniture or stored boxes Vents, ductwork, and false ceilings Exterior areas like woodpiles, sheds, and garden beds can also serve as breeding grounds. That's why a full-property inspection is essential to long-term control. Yosemite Pest's specialists are trained to detect these hiding spots and implement treatments that reach even the most inaccessible areas. In the era of Google's Search Generative Experience (SGE) and AI-curated results, people are turning to search engines with questions like: 'How do I get rid of spiders in my house in Naperville?' 'Are spider infestations dangerous in Illinois?' 'Affordable spider control near me' To show up in these AI-generated overviews, pest control companies must offer not only service—but authority. Yosemite Pest & Rodent Solutions provides science-based pest control, with verified EPA-compliant treatments and a transparent approach rooted in education and prevention. Spider activity in Naperville is more than seasonal—it's becoming a year-round concern due to shifting climate conditions and urban expansion. Whether you're dealing with a visible infestation or want to prevent one, professional spider control ensures your home remains safe, clean, and pest-free. With trusted providers like Yosemite Pest & Rodent Solutions, Naperville residents gain access to certified technicians, eco-friendly treatments, and long-term peace of mind—all without the need for a contract. In 2025, protecting your home starts with proactive pest control—and spiders are one problem you shouldn't ignore. TIME BUSINESS NEWS
Time Magazine
2 days ago
- Time Magazine
Cutting mRNA Research Could Be Our Deadliest Mistake Yet
The U.S. Department of Health and Human Services (HHS) recently announced it will wind down funding for mRNA vaccine development—which could prove to be one of the costliest, deadliest decisions HHS Secretary Robert F. Kennedy Jr. will make during his tenure. HHS has already scaled back access to and recommendations for COVID-19 vaccines—a decision experts are deeply concerned about—and Kennedy's frequently misinformed views on vaccines continue to fan the flames of anti-vaccination attitudes. Now, Kennedy's failure to fully explore the potential of mRNA vaccines could stagnate research that has the potential to save millions of lives around the world. The dark cloud of COVID-19, one of the deadliest infectious disease outbreaks in history, can hardly be thought of as having a silver lining. But the nearest thing to a glimmer of a positive would be that the fast development of COVID-19 vaccines helped prevent many more deaths and led to rapid progress in our understanding and use of mRNA technology. This greater understanding is now being explored as potential preventions or therapies for a wide range of diseases, from H5N1 bird flu and HIV to cancer. Terminating 22 mRNA projects will not only directly set back research on mRNA vaccines for infectious diseases including flu; it will also arguably have negative knock-on effects for researchers the world over exploring personalized treatments for noncommunicable diseases like cancer. Early research on some novel uses of mRNA is promising. For example, a preliminary trial of an mRNA HIV vaccine found that 80% of participants generated neutralizing antibodies, which in theory could help block HIV—pending further research and development. A melanoma mRNA vaccine, when combined with existing treatment, reduced the risk of death or disease recurrence by nearly 50%. (The vaccine is currently being tested further in a full scale Phase 3 clinical trial). Even more amazingly, personalized vaccines—where vaccines are created specifically for an individual using information from their cancer to optimize their immune response—using mRNA technology have even been proposed as a universal vaccine adaptable for all cancers. Read More: The CDC Shooting is a Dark Sign for Science and America Much of the research on personalized mRNA cancer vaccines is in some way indebted to gains in knowledge made from COVID-19 research, and it stands to reason that pulling such a large amount of funding from mRNA projects will slow down further progress in these areas. Approximately $500 million worth of research funding would almost certainly have advanced the scientific community's fundamental understanding of how, and to what extent, mRNA technology works and how it could be applied to prevent and fight disease. Also problematic is the manner in which HHS under Kennedy conveys their decisions. In announcing the funding withdrawal, HHS states it 'will focus on platforms with stronger safety records and transparent clinical and manufacturing data practices.' This implies that mRNA vaccines have not been properly or transparently tested—which is not true. The safety of COVID-19 mRNA vaccines has been demonstrated in numerous studies and systematic evidence reviews. Like pretty much all vaccines and treatments, mRNA vaccines are not without side effects, but evidence shows that any adverse events are nearly always mild and short-lived. COVID-19 vaccines have already saved millions of lives globally, with mRNA vaccines accounting for a significant majority of all doses administered in many countries. Kennedy's claim that 'mRNA technology poses more risk than benefits' is almost farcical in light of scientific evidence. Moreover, the whole purpose of clinical research is to test whether new scientific innovations—like novel applications of mRNA into different diseases—are safe and effective in the first place. Kennedy has long spoken of how we need more evidence and testing on mRNA vaccines, and so it is painfully ironic that he is pulling funding for research which would enable the scientific community to do just that. Read More: An mRNA Melanoma Vaccine Shows Promise Perhaps most concerning is the caliber of evidence upon which decisions with such massive implications are being made. In an HHS announcement of the termination of mRNA projects, Kennedy claims 'the data show these vaccines fail to protect effectively against upper respiratory infections like COVID and flu.' The truth is, initial vaccines and booster doses have been shown to be very effective against reducing infection, hospitalization, and death from COVID-19. Kennedy does not even provide links or citations to systematic reviews or meta-analyses in reputable journals, the gold standard methods for scientific evidence. Rather, he simply links to an online evidence review which cherry picks studies searching only for the harms—and not the overall safety, effectiveness, or cost-benefit analysis—of the mRNA vaccines. The report does not describe the methods used to select and review studies, nor does it appear itself to have been peer-reviewed by other scientists. It almost certainly wouldn't be publishable in a scientific journal, yet it is being used as evidence to justify the fate of half a billion dollars of research funds. This is another example of how fringe viewpoints on mRNA technology, instead of the best available scientific evidence, are under Kennedy and HHS becoming the new mainstream. The U.S. has been at the forefront of developing mRNA technology for the past few decades, from the Nobel Prize-winning research of professors Katalin Kariko and Drew Weissman at the University of Pennsylvania on mRNA, to the key role of U.S.-based pharmaceutical companies in vaccine production and rollout. Perhaps other countries, companies, and funding sources will offset this funding loss and lead the development of mRNA vaccine innovations. Large investments are already being made in the U.K. and China, for example. That would be to the detriment of U.S. scientific innovation and progress. Kennedy is right to scrutinize the potential overreach of the pharmaceutical industry, and to ensure their research and development is ethical and transparent. However, his seemingly personal war against "Big Pharma" and ideological opposition to mRNA risks stunting research that could one day help prevent the next pandemic or even provide cures for hitherto incurable cancers.
Business Wire
3 days ago
- Business Wire
Tivic Reports Second Quarter 2025 Financial Results
FREMONT, Calif.--(BUSINESS WIRE)-- Tivic Health® Systems, Inc. (NASDAQ: TIVC), a diversified immunotherapeutics company, today announced financial results for the second quarter and six months ended June 30, 2025. 'We have established a strong foundation for Tivic's strategic transformation with our expansion into biopharmaceuticals, making us unique in treating disease by addressing both the body's biochemical and bioelectronic systems,' stated Tivic CEO Jennifer Ernst. 'To maximize our focus on the compelling, late-stage clinical pipeline, we have increasingly shifted resources away from consumer healthtech and are now planning to exit the ClearUP business by the end of this year,' continued Ernst. 'I look forward to advancing the commercialization of these life-saving therapies, supporting our strategy to increase shareholder value through this transformation.' Corporate Highlights from the Second Quarter and Subsequent Weeks, included: Securing positive interest in potential military and defense applications for drug candidate Entolimod™ to treat ARS during briefings with the White House and U.S. Food & Drug Administration (FDA) officials. Extending the worldwide license of Entolimod™ to include the treatment of neutropenia, a condition that reduces the body's ability to combat infections and has a wide range of causes - from genetics to cancer treatments and age. Entering into a GMP manufacturing validation agreement with Scorpius Biomanufacturing, Inc. as part of preparing for the FDA biologics license application process. Completing all study visits in the Optimization Study for its patent-pending, non-invasive cervical vagus nerve stimulation (ncVNS) device. Raising $1.4 million from the first and second tranche of a preferred equity purchase agreement that provides for up to $8.4 million in total financing. Entering into a $25 million equity line of credit that generated net proceeds of $547,000. Receiving shareholder approval of key measures in support of Tivic transformation strategy. Expanding biopharmaceutical team with regulatory, clinical and business development staff. Naming Lisa Wolf as CFO following her nine-month tenure as interim CFO. Financial Performance: Revenue (net of returns) for the three and six months ended June 30, 2025 totaled $86,000 and $156,000, respectively, compared with $140,000 and $474,000 for 2024. The decreases are due to lower unit sales of ClearUP™ to treat sinus pain and pressure. The lower sales are attributable to decreases in advertising expenses as the company focused resources on accelerating its TLR5 program for the development of Entolimod™ for ARS. Gross profit in the three and six months ended June 30, 2025 was $54,000 and $104,000, respectively, compared to $30,000 and $197,000 in 2024. Gross margin was 67% in the six months ended June 30, 2025, compared to 42% in 2024. Operating expenses in the three and six months ended June 30, 2025 was $2.0 million and $3.5 million, respectively, compared to $1.3 million and $3.0 million in 2024. The increases were primarily due to the addition of the biopharma programs in February 2025. Net loss of $1.9 million for the three months ended June 30, 2025, compared to $1.3 million in the second quarter of 2024. Net loss of $3.4 million for the first half of 2025, compared to $2.7 million for the first half of 2024. At June 30, 2025, cash and cash equivalents totaled $1.2 million, compared with $2.0 million, at December 31, 2024. Subsequent to quarter's end, the Company raised a total of $0.9 million through utilization of its equity line of credit and the sale of Series B Preferred Stock pursuant to its preferred equity purchase agreement. The company has no debt on its balance sheet. Approximately $7.0 million remains available as a committed investment in Tivic through a preferred equity purchase agreement. The company believes the current and committed funding is sufficient to make meaningful progress toward manufacturing validation for Entolimod. Conference Call and Webcast Information Management will host a webcast/conference call today, Thursday, August 14, at 1:30 p.m. PT / 4:30 p.m. ET to discuss the company's second quarter 2025 financial results and provide a business update. Webcast Link An audio replay of the call will be available for the next 90 days from the investor page on the Tivic Health website at About Tivic Tivic's dual platform utilizes the body's biopharmaceutical and bioelectronic systems to treat unmet medical needs through targeting the immune system. Tivic's biologics compounds activate an innate immune pathway to prevent cell death in the bone marrow and epithelial tissues across systems impacted by radiation and age. The company's lead drug candidate, Entolimod™ for acute radiation syndrome, is a novel TLR5 agonist that has been granted Fast Track designation and is in late stage development. Tivic's bioelectronic program is developing a novel, non-invasive medical device designed to target the neural pathways implicated in many prevalent and debilitating diseases. Early trials show promising signals that Tivic's approach may regulate specific biologic responses, and the company believes its early-stage vagus nerve stimulation device has the potential to deliver clinical outcomes similar to or better than those of surgically implanted devices. To learn more about Tivic, visit: Forward-Looking Statements This press release may contain 'forward-looking statements' that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as 'anticipate,' 'believe,' 'contemplate,' 'could,' 'estimate,' 'expect,' 'intend,' 'seek,' 'may,' 'might,' 'plan,' 'potential,' 'predict,' 'project,' 'target,' 'aim,' 'should,' 'will,' 'would,' or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Tivic Health Systems, Inc.'s current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate, including as a result of interactions with and guidance from the FDA and other regulatory authorities; changes to the company's relationship with the its partners; the failure to obtain FDA or similar clearances or approvals and noncompliance with FDA or similar regulations; the company's future development of its ncVNS treatment, Entolimod and Entolasta; changes to the company's business strategy; timing and success of clinical trials and study results; regulatory requirements and pathways for approval; consummation of any strategic transactions; the company's need for, and ability to secure when needed, additional working capital; the company's ability to maintain its Nasdaq listing; and changes in tariffs, inflation, legal, regulatory, political and economic risks. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors. Accordingly, you are cautioned not to place undue reliance on such forward-looking statements. For a discussion of risks and uncertainties relevant to the company, and other important factors, see Tivic Health's filings with the SEC, including, its Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on March 21, 2025, under the heading 'Risk Factors," as well as the company's subsequent filings with the SEC. Forward-looking statements contained in this press release are made as of this date, and Tivic Health Systems, Inc. undertakes no duty to update such information except as required by applicable law. Tivic Health Systems, Inc. Condensed Statements of Operations (in thousands, except share and per share data) Three Months Ended June 30, Six Months Ended June 30, 2025 2024 2025 2024 REVENUES $ 86 $ 140 $ 156 $ 474 COST OF SALES 32 110 52 277 GROSS PROFIT 54 30 104 197 OPERATING EXPENSES Research and development 655 302 990 558 Sales and marketing 426 207 605 712 General and administrative 907 787 1,949 1,674 TOTAL OPERATING EXPENSES 1,988 1,296 3,544 2,944 NET OPERATING LOSS (1,934 ) (1,266 ) (3,440 ) (2,747 ) OTHER INCOME, NET 3 0 7 0 NET LOSS $ (1,931 ) $ (1,266 ) $ (3,433 ) $ (2,747 ) NET LOSS PER SHARE - BASIC AND DILUTED $ (2.19 ) $ (5.37 ) $ (4.64 ) $ (17.05 ) WEIGHTED-AVERAGE NUMBER OF SHARES - BASIC AND DILUTED 881,294 235,868 739,618 161,103 Expand
